Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer

Published:2012-07-01 Issue:2 Volume:70 Page:293-303
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Mardjuadi Feby,Medioni Jacques,Kerger Joseph,D’Hondt Lionel,Canon Jean-Luc,Duck Lionel,Musuamba Flora,Oudard Stephane,Clausse Marylene,Moxhon Anne,Machiels Jean-Pascal

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-012-1914-y.pdf

Reference44 articles.

1. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765–781

2. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

3. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520

4. De Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154

5. De Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CO-ADMINISTRATION OF TYROSINE KINASE INHIBITORS WITH ROTTLERIN IN METASTATIC PROSTATE CANCER CELLS;EXCLI J;2021

2. Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review;PLOS Biology;2017-02-03

3. Role of Sorafenib in Overcoming Resistance of Chemotherapy-Failure Castration-Resistant Prostate Cancer;Clinical Genitourinary Cancer;2014-04

4. Anti-proliferative actions of N′-desmethylsorafenib in human breast cancer cells;Biochemical Pharmacology;2013-08

5. Cell mates: paracrine and stromal targets for prostate cancer therapy;Nature Reviews Urology;2013-07-16